SNY and NVO Related Headlines
Go Back- Sanofi (SNY) Gains as Potential Insulin Competition from Novo (NVO) Put on Hold
- Amarin (AMRN) NCE Status Could Happen by September 14 and Takeover Could Follow - MKM
- Barclays Reiterates an 'Underweight' on Novo Nordisk (NVO); Shares Trading As If Not Risk Priced In
